1887
Volume 2022 Number 1
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

The ongoing coronavirus disease 2019 (COVID-19) pandemic has resulted in a global health emergency. With incomplete vaccination and incomplete protection of the vaccinated population, there remains an urgent need to develop drugs to treat COVID-19. Our previou analysis suggested vulnerability of SARS-CoV-2 to inactivation by the endogenous reactive metabolite, methylglyoxal (MG), by modification of arginine residues in the functional domains of viral spike and nucleocapsid proteins1–3. In this study, the antiviral activity of MG against wild-type SARS-CoV-2 using assays was evaluated. Wild-type SARS-CoV-2 with titers of multiplicities of infection (MOI) 0.8, 0.2, 0.02, and 0.01 were incubated with 2-fold serial dilutions of MG (7.8 μM to 500 μM) in infection medium for six hour. MG-treated and untreated control SARS-CoV-2 were incubated with confluent cultures of Vero cells for one hour, cultures were washed and then incubated in a fresh infection medium at 37°C for 4 - 5 days until 70% of virus–infected cells displayed cytopathic effect (CPE). The antiviral activity of MG was judged by assessing virus replication using quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and median tissue culture infectious dose (TCID) assays. MG inhibited virus replication as measured by PCR and CPE of SARS-CoV-2 , with TCID increasing with increasing MOI. MG was most potent at MOI 0.02 and 0.01 where EC of MG was 49.6 ± 4.7 μM and 28.5 ± 1.3μM; respectively. Similar findings were also found for a shorter incubation period (3 hours) of MG and virus. MG has inhibitory activity against wild-type SARS-CoV-2 for virus exposure in the cell-free systems at low MOI. However, the antiviral activity of MG against other SARS-CoV-2 variants including alpha- and beta-variants is being investigated. Drugs increasing cellular concentration of MG to viricidal levels may have anti-COVID-19 activity.

Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2022.qhc.8
2022-01-15
2022-09-28
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2022/1/jemtac.2022.qhc.8.html?itemId=/content/journals/10.5339/jemtac.2022.qhc.8&mimeType=html&fmt=ahah

References

  1. Al-Motawa MS, Abbas H, Wijten P, de la Fuente A, Xue M, Rabbani N, et al. Vulnerabilities of the SARS-CoV-2 Virus to Proteotoxicity—Opportunity for Repurposed Chemotherapy of COVID-19 Infection. Front Pharmacol [Internet]. 2020 Oct 9;11. Available from: https://www.frontiersin.org/article/10.3389/fphar.2020.585408/full .
    [Google Scholar]
  2. Rabbani N, Xue M, Thornalley PJ. Dicarbonyl stress, protein glycation and the unfolded protein response. Glycoconj J [Internet]. 2021 Jun 1;38:(3):331–40. Available from: https://link.springer.com/10.1007/s10719-021-09980-0 .
    [Google Scholar]
  3. Rabbani N, Thornalley PJ. Measurement of methylglyoxal by stable isotopic dilution analysis LC-MS/MS with corroborative prediction in physiological samples. Nat Protoc [Internet]. 2014 Aug 24;9:(8):1969–79. Available from: http://www.nature.com/articles/nprot.2014.129 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/jemtac.2022.qhc.8
Loading
  • Article Type: Conference Abstract
Keyword(s): antiviral.COVID-19methylglyoxal and SARS-CoV-2

Most Cited This Month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error